Trinity Partners Co-sponsors Panel Discussing Impact of Biosimilars on the Future of Affordable Medicine

Trinity Partners, a global life sciences consulting firm, today announced it is co-sponsoring a panel bringing together diverse perspectives from the life sciences ecosystem to discuss how biosimilars differ from generic products, FDA regulations and the cost of developing a biosimilar, and the implications for pharma, physicians and patients.
Sponsored by the Healthcare Businesswomen’s Association (HBA), the event will take place Wednesday, June 10 from 5:30- 8:30 p.m., EDT, at the Genzyme headquarters in Cambridge, MA.
Marie Sanchirico, director of Medical Managed Care at Genzyme, A Sanofi Company, will moderate the panel. Additional panelists include:
• Susan Dexter, principal consultant, Latham Biopharm
• Magdalena Leszcyniecka, president and CEO, STC Biologics, Inc
• Michael Wyand, chief technology officer, EPIRUS Biopharmaceuticals
“Changing regulations and a looming biotech patent cliff have created significant opportunity for biosimilars to boom in the global market over the next few years,” said Jillian Godfrey Scaife, Principal, Trinity Partners. “We look forward to hearing insights from industry leaders about this important new pathway and how it could revolutionize cost-effective healthcare.”
To learn more about the panel or if you are interested in attending, please visit:https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=4A3AFD7A-3EF8-E411-B471-0050569C00A7

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s